NCT07209527
Truway Diagnostic Tools in Primary Care
Enrolling by Invitation
EARLY_PHASE1All AgesInterventionalDiagnosticTruway Health, Inc.
~200 participants
Updated 2025-10-24 on ClinicalTrials.gov
What's tested:Truway Portable Ultrasound DeviceTruway Blood Glucose MonitorStandard Oral Hypoglycemic Agent
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of Early Detection of Chronic Conditions
Measured over 6 months
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesNew York1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Rate of Early Detection of Chronic Conditions6 months
The percentage of participants with early detection of chronic conditions (e.g., Type 2 Diabetes Mellitus, Cardiovascular Disease) using Truway Health-sourced portable diagnostic devices (ultrasound and blood glucose monitor) compared to standard care. Early detection is defined as identification of abnormalities (e.g., elevated HbA1c ≥5.7%, abnormal ultrasound findings) prior to clinical symptom onset.
- Improvement in Glycemic Control6 months
The change in HbA1c levels among participants with prediabetes or Type 2 Diabetes Mellitus in the intervention group using the Truway Blood Glucose Monitor and standard oral hypoglycemic agent, compared to the control group receiving standard care.